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claims, birth lists, medical records and meetings with Synagis nurses. Of the 714 infants who were identified as being potentially eligible to receive palivizumab, 374 were born during the study period. Of these, 367 infants met the study criteria (see 'Study Population' section) and were enrolled in the study. Participants were assigned to the prophylaxis group when there was documented evidence of having received at least one palivizumab injection during the study period. In the absence of such evidence, the participant was assigned to the non-prophylaxis group. Inpatient claims and RSV rapid antigen test results were screened to establish whether hospitalisation was caused by an RSV-related condition. Ambulatory care claims were based on diagnosis alone since RSV testing was not routinely performed by providers of ambulatory services. Four patients who were hospitalised with an RSV-related illness and subsequently received palivizumab prophylaxis were assigned to the non-prophylaxis group. This included one participant who was hospitalised with an RSV infection both before and after prophylaxis. A total of 185 patients were assigned to the prophylaxis group and 182 to the non-prophylaxis group.
Study design
The study employed a prospective cohort design and was multi-centred, with data being collected from 28 paediatric practices in North Carolina. The follow-up did not extend beyond the study period, which the authors variously described as being 7 or 8 months. Surveys were partially or fully completed for all study participants and risk factor data were completed for 98.4%.
Analysis of effectiveness
All of the patients included in the study were accounted for in the analysis. The primary health outcomes assessed were the number of hospitalisations for RSV-related conditions and the number of deaths. Other reported health care use was the average number of ambulatory care and emergency department visits, and the average number of palivizumab injections per participant.
A descriptive analysis was conducted to compare the predisposing, enabling and need factors between the two groups. The predisposing variables were those that "describe the propensity of individuals to use services" (i.e. in the study: race, gender, and age of participant's mother at the infant's date of birth). The enabling variables referred to resources that the patients and families required to use services (i.e. in the study: the highest educational level attained by the infant participant's mother and the number of miles the infant lived from a hospital that cares for infants or children or has an emergency department). The need variables referred to one's illness level or perceived need for care, as evaluated by the individual or the health care delivery system. The need variables selected for the study included whether an infant participant had a sibling in school, attended day care during the study period, was exposed to cigarette smoke in the home, or was part of a multiple birth.
Differences were tested using the chi-squared test for dichotomous variables and the t-test for continuous variables. The groups were similar in terms of patient gender, mother's age, distance to a health care facility for children, siblings in school, smoking exposure in the home, and the number of positive risk factors per participant. However, the prophylaxis group had a significantly greater percentage of white infants, a lower percentage of black and Hispanic infants, a higher percentage of multiple births, and were of slightly lower gestational age and weight at birth compared with the non-prophylaxis group. Multivariate regression analyses were undertaken to control for confounding by assessing the potential influence of risk factors on hospitalisation and costs.
Effectiveness results
The total number of hospitalisations for RSV-related conditions was 5 in the prophylaxis group versus 12 in the nonprophylaxis group, (p=0.0782). The participants in the prophylaxis group were hospitalised a total of 22 days (including 2 days in intensive care), compared with 45 days of hospitalisation (including 13 days in intensive care) for the nonprophylaxis group. When multivariate logistic regression was used to control for possible confounding factors, prophylaxis and non-prophylaxis participants did not differ in the incidence of hospitalisation for RSV-related conditions (odds ratio 0.27; p=0.058).
The average number of ambulatory care department visits per participant was 0.57 in the prophylaxis group and 0.63 in the non-prophylaxis group, (p=0.6539).
The average number of emergency department visits per participant was 0.05 in the prophylaxis group and 0.03 in the non-prophylaxis group, (p=0.3524).
The average number of palivizumab injections per participant was 4.10 in the prophylaxis group versus 0.07 in the nonprophylaxis group, (p<0.0001).
No deaths occurred in either group.
Clinical conclusions
There was no significant difference in the total number of hospitalisations for RSV-related conditions between participants who received prophylaxis and those who did not. The incidence of hospitalisation was still not statistically significantly different between the two groups when possible confounding factors were controlled for.
Measure of benefits used in the economic analysis
The measure of benefit used was the number of hospitalisations avoided.
Direct costs
Only the direct costs to the Medicaid programme were included in the analysis. These were for hospitalisation, emergency department care, ambulatory care (outpatient and office visit), and palivizumab prophylaxis. Resource use was taken from parental survey, medical record abstraction and North Carolina Medicaid claims. All costs were derived from Medicaid claims. Palivizumab costs were adjusted for the manufacturer's discount to the state Medicaid programmes according to the federal rebate programme, drug handling fees, and nurse visits for conservative cost estimates. The average per person seasonal cost was reported separately to the average resource use. Discounting was, appropriately, not undertaken. The cost data were collected for the years 2002 to 2003 and, although not explicitly stated, the costs were presumed to be expressed in these prices.
The study reported the average and standardised costs per person for the RSV season (i.e. 7 months). Standardised costs were used to account for those infants who were born during the study and did not complete the full study period. Standardised costs were calculated as the actual per person cost divided by the number of months the patient was in the study, and then multiplied by 7 months. relevant categories of costs were included in the analysis. Some relevant costs were omitted from the analysis. For example, the authors did not include the costs of side effects of treatment, and it is unclear whether their omission would have affected the authors' conclusions. Average per person seasonal costs were reported separately to average per person seasonal health care use, thus enhancing the reproducibility of the study in other settings. However, the accuracy of the estimates of the average costs is uncertain as the authors reported that the data were collected from 1 October 2002 to 31 May 2003 (i.e. 8 months), yet the study was conducted over 7 months.
No statistical analyses of either the quantities or prices were performed. A sensitivity analysis was undertaken to explore the impact of RSV test sensitivity on the costs, and the rational for the range used appears to have been appropriate. Discounting was not applied, which was appropriate given that the costs were incurred only during a short time. Costs, rather than charges, were reported. The price year was inferred to be 2002 to 2003, and this increases the generalisability of the results.
